SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications
Target(TGT) GlobeNewswire News Room·2024-12-11 11:30
U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device (SCD) in five ...